Virus strains
AssigneeBiovex Limited
InventorRobert S. Coffin
Life of this patent
Estimating the term…
Abstract
The present invention relates to clinical herpes simplex virus (HSV) isolates with improved oncolytic capabilities as compared to reference laboratory HSV strains. The present invention also relates to methods of producing HSV strains of the invention and to pharmaceutical compositions comprising a HSV strain of the invention.
Claims10
A herpes simplex virus 1 (HSV1) strain, which is modified such that it lacks one or more of a functional ICP34.5-encoding gene, a functional ICP6-encoding gene, a functional glycoprotein H-encoding gene and a functional thymidine kinase-encoding gene, and which is derived from HSV1 strain JS1 as deposited at the European Collection of Cell Cultures (ECACC) under accession number 01010209.
Dependencies are inferred from the claim text.